Skip to main
RXRX

Recursion Pharmaceuticals (RXRX) Stock Forecast & Price Target

Recursion Pharmaceuticals (RXRX) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 25%
Buy 25%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Recursion Pharmaceuticals is a leading company in the emerging field of machine learning and artificial intelligence applied to drug discovery, with major partnerships and significant opportunities in rare diseases. The company has a strong financial position with enough cash to fund operations into early 2028 and has several ongoing clinical programs that serve as a proof-of-concept for its platform. The upcoming feedback from the FDA on potential registrational study designs for REC-4881 in FAP is a major value driver for the company.

Bears say

Recursion Pharmaceuticals is a clinical-stage biotechnology company with promising technology and partnerships in the industry, including a recent milestone payment from Sanofi and a partnership with Roche. However, the company's clinical programs are still in early stages and there is no guarantee of success. Additionally, the company faces competition from other companies applying ML/AI to drug discovery. With ongoing clinical programs primarily serving to validate the platform's value, the company's collaborations with pharma partners will likely be the key driver of value.

Recursion Pharmaceuticals (RXRX) has been analyzed by 4 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 25% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Recursion Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Recursion Pharmaceuticals (RXRX) Forecast

Analysts have given Recursion Pharmaceuticals (RXRX) a Buy based on their latest research and market trends.

According to 4 analysts, Recursion Pharmaceuticals (RXRX) has a Buy consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Recursion Pharmaceuticals (RXRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.